EP-101 STEMVAC
/ EpiThany, University of Washington
- LARVOL DELTA
Home
Next
Prev
1 to 15
Of
15
Go to page
1
October 17, 2025
STEMVAC in Patients With Early Stage Triple Negative Breast Cancer
(clinicaltrials.gov)
- P2 | N=33 | Active, not recruiting | Sponsor: University of Washington | Recruiting ➔ Active, not recruiting | Trial completion date: Jun 2026 ➔ Jul 2028 | Trial primary completion date: Dec 2025 ➔ Jul 2026
Enrollment closed • Trial completion date • Trial primary completion date • Breast Cancer • Hormone Receptor Negative Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • ER • HER-2 • PGR
October 02, 2025
A Vaccine (STEMVAC) With Standard Endocrine-Based Therapy or Chemotherapy for the Treatment of Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer
(clinicaltrials.gov)
- P2 | N=40 | Recruiting | Sponsor: University of Washington | Not yet recruiting ➔ Recruiting
Enrollment open • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor
August 26, 2025
A Multiple Antigen Vaccine (STEMVAC) for the Treatment of Patients With Stage IV Non-Small Cell Lung Cancer
(clinicaltrials.gov)
- P2 | N=5 | Active, not recruiting | Sponsor: University of Washington | N=40 ➔ 5
Enrollment change • Lung Cancer • Lung Non-Squamous Non-Small Cell Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • ENG
August 18, 2025
A Vaccine (STEMVAC) With Standard Endocrine-Based Therapy or Chemotherapy for the Treatment of Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer
(clinicaltrials.gov)
- P2 | N=40 | Not yet recruiting | Sponsor: University of Washington
New P2 trial • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor
July 25, 2025
A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast Cancer
(clinicaltrials.gov)
- P2 | N=20 | Not yet recruiting | Sponsor: University of Washington
New P2 trial • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • ENG
June 30, 2025
A Multiple Antigen Vaccine (STEMVAC) for the Treatment of Patients With Stage IV Non-Small Cell Lung Cancer
(clinicaltrials.gov)
- P2 | N=40 | Active, not recruiting | Sponsor: University of Washington | Recruiting ➔ Active, not recruiting
Enrollment closed • Lung Cancer • Lung Non-Squamous Non-Small Cell Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • ENG
June 09, 2025
STEMVAC in Patients With Early Stage Triple Negative Breast Cancer
(clinicaltrials.gov)
- P2 | N=33 | Recruiting | Sponsor: University of Washington | Trial completion date: Dec 2025 ➔ Jun 2026 | Trial primary completion date: Apr 2025 ➔ Dec 2025
Trial completion date • Trial primary completion date • Breast Cancer • HER2 Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Negative Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • ER • HER-2 • PGR
April 03, 2025
The potential of ARL4C and its-mediated genes in atherosclerosis and agent development.
(PubMed, Front Pharmacol)
- "Many agents, including ABCA1 agonists (CS-6253, IMM-H007, RG7273, and R3R-01), FLNA antagonist sumifilam, LRP6 inhibitor BI-905677 and agonist SZN-1326, and SOX2 inhibitor STEMVAC, were investigated in clinical trials. Thus, ARL4C and its regulated genes may be a potential target for drug development. Thus, we focus on the role of ARL4C and its-mediated genes in atherosclerosis and agent development, which provide insights for the identification, research, and drug development of novel targets."
Journal • Review • Atherosclerosis • Cardiovascular • Colorectal Cancer • Hepatology • Liver Cancer • Lung Adenocarcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • ABCA1 • ALDH1A3 • SNAI2 • SOX2
March 25, 2024
STEMVAC in Patients With Early Stage Triple Negative Breast Cancer
(clinicaltrials.gov)
- P2 | N=33 | Recruiting | Sponsor: University of Washington | Trial completion date: Apr 2024 ➔ Dec 2025 | Trial primary completion date: Apr 2024 ➔ Apr 2025
Trial completion date • Trial primary completion date • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Negative Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • ER • HER-2 • IFNG • PGR
January 23, 2024
A Multiple Antigen Vaccine (STEMVAC) for the Treatment of Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer
(clinicaltrials.gov)
- P2 | N=40 | Recruiting | Sponsor: University of Washington | Trial completion date: Jan 2026 ➔ Dec 2026 | Trial primary completion date: Jan 2024 ➔ Dec 2025
Metastases • Trial completion date • Trial primary completion date • Lung Cancer • Lung Non-Squamous Non-Small Cell Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • CD4
October 06, 2022
Optimizing immunization schedules for therapeutic vaccination
(SITC 2022)
- P1 | "We evaluated immunization schedules with a 5-antigen, multi-epitope plasmid DNA vaccine, STEMVAC, targeting cancer stem cell associated proteins...Conclusions Varying the time between immunizations can significantly impact the quality of the T-cell response to a mulit-antigen plasmid-based vaccine. Further studies are ongoing to correlate these differences to anti-tumor activity."
Breast Cancer • Oncology • Solid Tumor • CSF2 • IFNG
December 02, 2022
A Multiple Antigen Vaccine (STEMVAC) for the Treatment of Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer
(clinicaltrials.gov)
- P2 | N=40 | Recruiting | Sponsor: University of Washington | Not yet recruiting ➔ Recruiting
Enrollment open • Lung Cancer • Lung Non-Squamous Non-Small Cell Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • CD4 • CDH3 • ENG • IFNG • SOX2 • TRB
October 06, 2022
A Phase I dose escalation study of STEMVAC, a multi-antigen, multi-epitope Th1 selective plasmid-based vaccine, targeting stem cell associated proteins in patients with advanced breast cancer
(SITC 2022)
- P2 | "Conclusions STEMVAC selectively elicits high level persistent Type I T-cell responses at the 300mcg dose. Two Phase II studies are enrolling; adjuvant setting for TNBC ( NCT05455658 ) and maintenance therapy with pembrolizumab in metastatic non-small cell lung cancer ( NCT05242965 )."
Clinical • P1 data • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • CDH3 • CSF2 • ENG • HER-2 • IFNG • IL10 • SOX2
November 03, 2022
STEMVAC in Patients With Early Stage Triple Negative Breast Cancer
(clinicaltrials.gov)
- P2 | N=33 | Recruiting | Sponsor: University of Washington | Not yet recruiting ➔ Recruiting
Enrollment open • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Negative Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • CD69 • CD8 • ER • FOXP3 • GATA3 • HER-2 • IFNG • LAG3 • PGR • TNFRSF9 • TRB
July 13, 2022
STEMVAC in Patients With Early Stage Triple Negative Breast Cancer
(clinicaltrials.gov)
- P2 | N=33 | Not yet recruiting | Sponsor: University of Washington
New P2 trial • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Negative Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • CD44 • CD69 • CD8 • ER • FOXP3 • GATA3 • HER-2 • IFNG • LAG3 • PGR • TNFRSF9 • TRB
1 to 15
Of
15
Go to page
1